Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03396952 · ClinicalTrials.gov registry record · Phase 2
Prostaglandin Inhibition and Immune Checkpoint Blockade in Melanoma
A Phase 2 study, sponsored by University of California, San Francisco.
- Completed
- Registry status
- Phase 2
- Development phase
- 27
- Enrollment target
NCT03396952 is a Phase 2 study that has completed, run by University of California, San Francisco. The registered enrollment target is 27 participants.
The verdict
NCT03396952, a Phase 2 study, has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 27 participants
- Enrollment target
Study Summary
This phase II trial studies how well pembrolizumab, ipilimumab, and aspirin work in treating patients with melanoma that has spread to other places in the body or cannot be removed by surgery. Monoclonal antibodies, such as pembrolizumab and ipilimumab, may interfere with the ability of tumor cells to grow and spread. Aspirin may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving pembrolizumab, ipilimumab, and aspirin may work better in treating patients with melanoma.
Interventions
- BIOLOGICAL Pembrolizumab
- OTHER Laboratory Biomarker Analysis
- DRUG Aspirin
- BIOLOGICAL Ipilimumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2018-04-19 |
| Est. Completion | 2022-06-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03396952
The ClinicalTrials.gov registry entry for NCT03396952 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Pembrolizumab is the first listed.
NCT03396952 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03396952 about?
NCT03396952 is a clinical study titled "Prostaglandin Inhibition and Immune Checkpoint Blockade in Melanoma". This phase II trial studies how well pembrolizumab, ipilimumab, and aspirin work in treating patients with melanoma that has spread to other places in the body or cannot be removed by surgery. Monoclonal antibodies, such as pembrolizumab and ipilimumab, may interfere with the ability of tumor cells ...
What is the current status of trial NCT03396952?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 27 participants. The study started on 2018-04-19. Estimated completion is 2022-06-30.
What interventions are being tested in trial NCT03396952?
The interventions under investigation include: Pembrolizumab (BIOLOGICAL), Laboratory Biomarker Analysis (OTHER), Aspirin (DRUG), Ipilimumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT03396952?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.